Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.35 USD
Change Today -0.16 / -4.56%
Volume 800.0K
CYTR On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

cytrx corp (CYTR) Snapshot

Open
$3.46
Previous Close
$3.51
Day High
$3.48
Day Low
$3.30
52 Week High
06/13/14 - $5.46
52 Week Low
12/16/14 - $2.08
Market Cap
186.7M
Average Volume 10 Days
721.6K
EPS TTM
$-0.55
Shares Outstanding
55.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTRX CORP (CYTR)

Related News

No related news articles were found.

cytrx corp (CYTR) Related Businessweek News

No Related Businessweek News Found

cytrx corp (CYTR) Details

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with soft tissue sarcoma; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase 2b and Phase 1b/2 clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

26 Employees
Last Reported Date: 03/10/15
Founded in 1985

cytrx corp (CYTR) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.3M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $450.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $825.0K
Senior Vice President of Drug Development
Total Annual Compensation: $650.0K
Senior Vice President of Legal Affairs, Gener...
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2014.

cytrx corp (CYTR) Key Developments

CytRx Corporation Reports Earnings Results for the Year Ended December 31, 2014

CytRx Corporation reported earnings results for the year ended December 31, 2014. For the year, the company reported licensing revenue of $100,000, compared to $300,000 for the year ended December 31, 2013. Loss before other income for the year ended December 31, 2014 was $49.60 million, compared to a loss before other income of $27.59 million for the year ended December 31, 2013. Interest income for the year ended December 31, 2014 was $305,331, compared to $137,676 for the year ended December 31, 2013.

CytRx Corporation Appoints Anita Chawla to its Board of Directors

On March 9, 2015, the Board of Directors of CytRx Corporation appointed Anita Chawla, Ph.D., to the company’s Board of Directors. Dr. Chawla was appointed as a Class II director with a term that expires at the 2017 meeting of stockholders. Dr. Chawla was also appointed to serve on the company’s Compensation Committee and Nominating and Corporate Governance Committee. Dr. Chawla is an economist with more than 25 years of experience in the health care sector. She has extensive experience using economic analyses to support the business objectives of life sciences companies. Dr. Chawla is a Managing Principal at Analysis Group Inc. Prior to joining Analysis Group in 2007, she was head of the Health Economics & Outcomes Research department at Genentech Inc. from 2001 to 2006. She has also held positions at Thomson Medstat, Research and Policy Division (1993-2000) and the American Medical Association, Center for Health Policy Research (1989-1993). Dr. Chawla is no relation to any other Company employees named Chawla.

CytRx Corporation Reports Earnings Results for the Year Ended December 31, 2014

CytRx Corporation reported earnings results for the year ended December 31, 2014. For the year, the company's net loss was $30.1 million or $0.55 per basic and diluted share compared with $47.5 million or $1.44 per basic and diluted share a year ago. Cash used for operating activities for that period was $40.6 million compared with $23.8 million a year ago. Revenue was $0.1 million compared with $0.3 million a year ago. Loss before provision for income taxes was $30.1 million compared with $47.5 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTR:US $3.35 USD -0.16

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies
 

Industry Analysis

CYTR

Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,956.1x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,177.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTRX CORP, please visit www.cytrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.